Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA agrees to special protocol assessment for AMD clinical trial ➤ Topline data from Phase 2 trial evaluating suprachoroidal wet AMD treatment ➤ First patient dosed in Phase 1 DME treatment study ➤ Study: new gene variants contributing to glaucoma susceptibility identified ➤ ASCRS news and events
➤ FDA approves updated femtosecond laser for refractive surgery ➤ Positive topline results from Phase 3, first-in-class dry eye disease studies ➤ Rare Disease Designation granted for investigational gene therapy ➤ Positive interim data for investigational Stargardt disease treatment ➤ First patient dosed in Phase 2 trial for DME treatment ➤ Research program established to investigate whole eye transplant ➤ ASCRS news and events
➤ FDA approves new excimer laser technology ➤ Phase 3 trial to evaluate phentolamine for treatment of decreased visual acuity ➤ Phase 2 trial of investigational dry eye drug sees effect on signs and symptoms ➤ Study has new findings to promote corneal healing ➤ ASCRS news and events
➤ ASCRS advocacy helps protect MIGS coverage ➤ FDA approves generic loteprednol etabonate ophthalmic suspension ➤ Orphan Drug Designation granted for corneal endothelial cell substitute ➤ Positive results in Phase 2 clinical trial for contact lens discomfort ➤ First patient visits ➤ Acquisition news ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Positive topline results in Phase 2a trial for treatment of MGD in patients with Demodex ➤ First patient visit in Phase 2b trial evaluating anti-TNFα for dry eye disease ➤ Smart contact lens makes progress ➤ Asset transition ➤ ASCRS news and events
➤ Primary, secondary endpoints met in Phase 2 wet AMD trial ➤ Modifications made to investigational glaucoma treatment device ➤ Positive Phase 1/2 data from clinical trial for treatment of Leber congenital amaurosis ➤ Results from first-in-human study of siRNA treatment for AMD ➤ Possibility of a minimally invasive approach for treating AMD ➤ ASCRS news and events
➤ First patient treated in Phase 2 study of investigational emulsion for glaucoma ➤ FDA issues complete response letter for dry eye drug NDA ➤ FDA meeting minutes issued for BLA submissions of ophthalmic formulation of bevacizumab ➤ Phase 1/2 trial to begin for first-in-class dry AMD therapy ➤ Company merger news ➤ ASCRS news and events
➤ World’s first whole-eye transplant ➤ Regenerative Medicine Advanced Therapy designation for investigational therapy for Leber congenital amaurosis ➤ 48-month trial data for retinal prosthesis for patients with severe atrophic AMD ➤ First patient dosed in Phase 1/2 trial for Stargardt disease gene therapy ➤ Partnership to develop molecule targeting DME ➤ ASCRS news and events
➤ 3-year efficacy and safety results of gene therapy for wet AMD reported ➤ Phase 2 trial results of gene therapy for diabetic retinopathy ➤ Phase 2 program for tracking glaucoma biomarkers begins ➤ Results from extension study of the first approved treatment for geographic atrophy ➤ Primary endpoint agreed upon for investigational oral diabetic retinopathy therapy ➤ ASCRS news and events
➤ FDA expands eye drop warning list ➤ Positive results in Phase 2a trial for new biodegradable sustained drug delivery implant ➤ Phase 2b study begins for investigational therapy for acute infectious conjunctivitis ➤ FDA approves additional treatment indication for bispecific antibody ➤ Enrollment complete for study evaluating femtosecond laser-created trabeculotomy ➤ Company to study personalized medicine for patients with wet AMD ➤ Enrollment complete for Phase 2b trial evaluating wet AMD therapy ➤ Pivotal trial for wet AMD therapy begins ➤ Survey evaluates female ophthalmologist experiences ➤ ASCRS news and events
Get the latest ophthalmology news delivered to your inbox every Friday.